UnknownPhase 2NCT05190627

Effect of Loratadine in Lymphangioleiomyomatosis

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut d'Investigació Biomèdica de Bellvitge
Principal Investigator
Maria Molina-Molina, MD, PhD
Institut d'Investigació Biomèdica de Bellvitge
Intervention
Loratadine(drug)
Enrollment
62 enrolled
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05190627 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials